Mainehealth

Mainehealth, a Portland, Maine-based nonprofit healthcare system, operates as a federal grant recipient (42% of recent awards) and as a subcontractor on grants and research projects (58% of recent awards). The organization competes across full-and-open funding without set-asides, serving as both an institutional healthcare provider—delivering community nursing home services to veterans—and a biomedical research entity through its Maine Medical Center Research Institute. Mainehealth does not hold federal contract vehicles.

Mainehealth's federal award footprint spans 505 recent awards with combined potential value of $13.4 million as the acting party, though obligated dollars total $872.8 million, reflecting substantial downstream federal funding flowing through grants to subrecipients and sub-award flows. The activity trajectory shows acceleration: 28 awards in 2022 grew to 110 in 2024, before moderating to 87 in 2025 and 39 through September 2026. The organization serves 73 distinct customer agencies across a broad portfolio. Customer concentration is dispersed: the Federal Emergency Management Agency leads by award count with 74 awards (largely centered on COVID-19 labor and materials support), while the Department of Health and Human Services dominates by dollar value, with the National Institutes of Health National Institute of Child Health and Human Development anchoring 13 awards valued at $11.9 million combined potential value. The Department of Veterans Affairs Veterans Integrated Service Network 1 contributes seven awards worth $660 thousand, primarily for community nursing home services.

Capability work splits between healthcare delivery and biomedical research. On the contract side, Mainehealth holds a single-award Indefinite Delivery Contract with VISN 1 (awarded February 2024, $355,777 ceiling through January 2029) for community nursing home services to veterans across New England; task orders for community nursing home express-report services ran $101 thousand to $122 thousand in 2024–2025. A sole-source $52,716 purchase order from VISN 21 (awarded September 2025, completing September 2026) supports specialized research laboratory analysis of serum and plasma specimens measuring bone marrow fat and skeletal health markers in type 2 diabetes veterans. The organization was selected based on specialized capabilities and advanced instrumentation available only in dedicated research settings, backed by internationally recognized physician-scientists in endocrinology.

On the research grant side, Mainehealth acts as prime recipient on NIH-funded project grants spanning infectious disease, metabolic and endocrine disease, neurodevelopmental biology, environmental health, and clinical training. Representative awards include a $489,848 National Institute of Allergy and Infectious Diseases Project Grant (awarded September 2026, through August 2028) investigating combination therapy targeting MRSA in cystic fibrosis patients; a $2.61 million National Institute of Diabetes and Digestive and Kidney Diseases Project Grant (September 2025 through August 2029) on gastric endocrine functions in skeletal homeostasis following bariatric surgery; a $466,738 National Institute of Mental Health Project Grant (June 2026 through March 2031) on allelic DIO3 control of brain development in neurodevelopmental disorders using transgenic mouse models; and a $187,235 National Heart Lung and Blood Institute career development award (August 2026 through July 2031) on night shift work, sleep, and perinatal cardiometabolic health among healthcare workers. Mainehealth also received a $2.2 million Defense Health Agency Military Medical Research and Development grant (June 2025 through June 2028) investigating tranexamic acid efficacy in reducing capillary leak and fluid resuscitation requirements after severe burn injury. SAMHSA and CDC funding supports community health programs including a $1.4 million CDC Cooperative Agreement (September 2025 through September 2030) to evaluate a community-based drug checking navigator intervention for overdose prevention, and a $125 thousand Drug-Free Communities Support Program award (July 2026 through June 2031) to reduce marijuana and alcohol use among youth in twelve Maine towns.

Mainehealth operates as a subcontractor on research grants led by Mayo Clinic, Stanford, Tufts University, Yale University, The General Hospital Corporation, Cornell University, and other research institutions. Sub-award work includes participation in the REACT-AF arrhythmia trial, Lyme disease surveillance using electronic health records coordination across Massachusetts General Hospital and Tufts Medicine, cystic fibrosis lung transplant preparation studies, osteoporosis drug therapy comparative effectiveness research, and vector-borne disease epidemiology training. The Maine Medical Center Research Institute (a Mainehealth entity) operates core research facilities including a small animal imaging core supporting 15 major and 3 minor users with 8 R01-funded projects.

The organization reports minimal SCI-reportable federal services activity: 0.1 FTEs recorded in FY2024 on a single named subcontractor record, reflecting that Mainehealth's federal footprint is dominated by grants and research awards rather than labor-based service contracts above the $150,000 reporting threshold. Recompete exposure in the next twenty-four months totals 27 awards with $50 thousand combined potential value—primarily small grant completions rather than contract roll-offs.